AzTrials
AzTrials

COVID-19 PneumoniaPhase 1NCT05212532

A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

A Phase 1 study testing EOM613 in people with COVID-19 Pneumonia and COVID-19 Respiratory Infection, run by EOM Pharmaceuticals at 4 sites in Brazil.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections. This proof-of-concept study is the first clinical trial of EOM613 in this patient population. Read more about this study

Who is it for?
Ages 18 to 84 years
What is being tested?
EOM613
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
4 sitesBrazil
Study dates
9 Aug 2021to 30 Mar 2022
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 84 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult
  1. Inclusion Criteria
  2. Non-ICU cohort:
  • Males or females ≥18 years and < 85 years of age
  • Positive test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) by nasopharyngeal sampling using a reliable nucleic acid Reverse Transcription-Polymerase Chain Reaction (RT-PCR) assay or fast serological tests confirmed by RT PCR afterward
  • Hospitalized for Acute Respiratory Distress Syndrome (ARDS) or pneumonia
  • Requires oxygen therapy by nasal catheter or mask, but not invasive mechanical ventilation at the enrollment
  1. ICU cohort:
  • Males or females ≥18 years and < 85 years of age
  • Positive test for SARS-CoV-2 by nasopharyngeal sampling using a reliable nucleic acid RT-PCR assay
  • Hospitalized for ARDS or pneumonia and requires invasive mechanical ventilation at enrollment
  1. Both cohorts:
  • Participant or suitable proxy able to provide written informed consent before study procedures are performed
  • Able to adhere to the study schedule and other protocol requirements
  • No known contraindications for administering EOM613, including Mycobacterium tuberculosis infection (assessed by the anamnesis) or receiving immunosuppressant therapy after transplant
  • Not enrolled in another study of an investigational agent during this study
  • Patients who developed complications of COVID-19 (such as myocardial disease, kidney dysfunction, clotting disorder, encephalitis, severe fatigue, or multi-immune inflammatory syndrome) are eligible
  1. Exclusion Criteria
  2. Both cohorts:
  • Active participation in any other clinical trial of an experimental treatment for COVID-19
  • Participation in another clinical trial with any investigational new drug within 12 months before enrollment, except if there is a possible benefit to the participant in the investigator's opinion (According to the Brazilian Resolution CNS 251/97 II.2-J)
  • Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 is prohibited <24 hours before study medication initiation
  • Sequential Organ Failure Assessment Score >10
  • Stage 4 severe chronic kidney disease or requiring dialysis (i.e., estimated Glomerular Filtration Rate [eGFR] <30)
  • Active cancer receiving any therapeutic intervention or under palliative care
  1. Both cohorts, conditions existing before COVID-19:
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Heart failure or cardiomyopathies
  • Sickle cell disease
  • Solid-organ transplantation
  • Uncontrolled or poorly controlled Type 2 diabetes mellitus
  • Immunodeficiency or immunosuppressive therapy
  • Pregnant or breastfeeding
  • Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment
  • Known active Mycobacterium tuberculosis infection (assessed by the anamnesis)
  • Patients who are unwilling or unable to follow protocol requirements
  • Patients with body mass index (BMI) < 18 kg/m2 or > 40 kg/m2

Trial locations and contacts

4 sites in 1 country.

Melina Szkelnik-Sidi, BS contact

+ 55 11 98258-6261

melina.sidi@azidusbrasil.com.br

Brazil4 sites, 4 recruiting

  • Hospital de Amor

    Barretos, São Paulo, 14784-400

    César Maurício, MD, cesarms.research@gmail.com

    Letícia Barbieri, barbieri.pesquisaclinica@hcancerbarretos.com.br

    Recruiting

  • Hospital Municipal de Barueri

    Barueri, São Paulo

    Paulo Tierno, paulo.tierno@hmb.spdm.org.br

    Marielle Nunes, sc@brtrials.com.br

    Recruiting

  • Casa De Saúde

    Boqueirão, São Paulo

    Florentino Cardoso Filho, MD, PhD, +55 19 991232882, florentino.cardoso@hospitalcare.com.br

    Jomenica do Livramento, 13 3202 2500, jomenica@casadesaudecampinas.com.br

    Recruiting

  • Oswaldo Cruz

    Manguinhos, Rio de Janeiro, 21040-900

    Elie Fiss, MD, PhD, 0xx21)2598-4242, eliefiss@uol.com.br

    Evelyn Cristina C Da Silva, 0xx21)2598-4242, eccsilva@haoc.com.br

    Recruiting

Other trials in Brazil

About this study

Official title: A Proof-of-Concept Study Evaluating Safety, Tolerability, and Preliminary Efficacy of EOM613 in COVID-19 Infected Patients With Severe Symptoms

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections. This proof-of-concept study is the first clinical trial of EOM613 in this patient population.

Read the detailed description

Much of the morbidity and mortality in COVID-19 infection is thought to be the result of an overly zealous attack by the immune system (e.g., cytokine storm and IL-6 elevations) as it attempts to counteract the viral infection. Some drugs with immunomodulatory effects (e.g., dexamethasone, tocilizumab) have been shown to reduce virus-induced cytokine storms and key pro-inflammatory cytokines, including IL-6.

EOM613 is a peptide nucleic acid with novel immune-modulating properties, including modulation of IL-6 expression. It has an excellent safety profile and has yielded promising therapeutic results in patients with Acquired Immunodeficiency Syndrome (AIDS), cancer cachexia and severe rheumatoid arthritis. EOM613 was reported to have antiviral activity in cell cultures inoculated with Human Immunodeficiency Virus (HIV) or adenovirus. This proof-of-concept study is the first clinical trial of EOM613 in patients with COVID-19 infection.

This study will include two cohorts of hospitalized patients, non-ICU and ICU. In non-ICU patients, EOM613 is to be administered subcutaneously (SC) at a dose of 2 mL once daily (QD) for 10 days, for a total of 20 mL. In ICU patients, EOM613 is to be administered SC at a dose of 2 mL twice daily (BID) for 5 days followed by 2 mL QD for 5 days, for a total of 30 mL.

The primary objective and outcome measures include assessment of safety and tolerability of EOM613, based on clinical laboratory, physical exams, and assessment of adverse events (AEs). The secondary objectives and outcome measures are 1) The proportions of non-ICU patients discharged with and without progression to invasive mechanical ventilation or ICU; 2) The proportion of ICU patients who die, are discharged to the infirmary, or discharged from the hospital; and 3) Assessment of levels of pro- and anti-inflammatory cytokines in Cytokine Panel 13, and their correlations with primary and secondary endpoints.

Being tested
EOM613
Keywords
Cytokines, Chemokines, COVID-19, SARS-CoV-2, Immune modulation
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EOM613Drug

    peptide nucleic acid (PNA)

Study groups in NCT05212532
Study groupRoleWhat they receive
non-ICU hospitalizedExperimentalPatients who are hospitalized at study enrollment but are not being treated in the ICU
Receives: Drug: EOM613
ICU hospitalizedExperimentalPatients who, at study enrollment, are being treated in the hospital ICU
Receives: Drug: EOM613

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline to day 11 in mean blood urea nitrogen (BUN) level.

    The BUN primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (BUN is also assessed on days 2, 5, and 8). BUN is obtained from a venous blood draw and measured in millimoles of urea per liter. 2.1 to 8.5 mmol/L is considered normal; values above 8.5 mmol/L may indicate renal impairment.

    Measured: Baseline and day 11 or discharge, whichever comes first.

  2. Change from baseline to day 11 in mean blood creatinine level.

    The blood creatinine primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (blood creatinine is also assessed on days 2, 5, and 8). Blood creatinine is obtained from a venous blood draw and measured in micromoles of creatinine per liter. 65.4 to 119.3 micromoles/L in adult women and 52.2 to 91.9 micromoles/L in adult men are considered normal; values above these ranges may indicate renal impairment.

    Measured: Baseline and day 11 or discharge, whichever comes first.

  3. Change from baseline to day 11 in mean blood lymphocyte count.

    The blood lymphocyte count primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (blood lymphocyte count is also assessed on days 2, 5, and 8). Blood lymphocyte count is obtained from a venous blood draw and measured as the number of lymphocytes per microliter of blood. Between 1,000 and 3000 lymphocytes per microliter of blood is considered normal. Values below this range have correlated with the severity of COVID-19 infection; values above this range can be indicative of an infection, cancer of the blood or lymphatic system, or an autoimmune disorder.

    Measured: Baseline and day 11 or discharge, whichever comes first.

  4. Change from baseline to day 11 in mean serum soluble interleukin-2 receptor (sIL-2R) level.

    The serum sIL-2R primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (serum sIL-2R will also be assessed on days 2, 5, 8, 14 and 28). Serum sIL-2R levels are measured with a Quantitative Multiplex Bead Assay. The normal range has been reported as 175.3 - 858.2 pg/mL. Elevated levels are found in individuals with severe inflammatory conditions and solid tumors.

    Measured: Baseline and day 11 or discharge, whichever comes first.

  5. Change from baseline to day 11 in mean serum interleukin-6 (IL-6).

    The serum IL-6 primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (serum IL-6 will also be assessed on days 2, 5, 8, 14 and 28). Serum IL-6 levels are measured with a Quantitative Multiplex Bead Assay. Normal values have been reported as <2.0 pg/mL. Elevated levels are associated with inflammatory conditions and predict lower chances of survival in COVID-19 patients.

    Measured: Baseline and day 11 or discharge, whichever comes first.

  6. Change from baseline to day 11 in mean serum interleukin-10 (IL-10) levels.

    The serum IL-10 primary outcome measure is its change from baseline to day 11 or discharge, whichever comes first (serum IL-10 will also be assessed on days 2, 5, 8, 14 and 28). Serum IL-10 levels are measured with a Quantitative Multiplex Bead Assay. Normal values have been reported as <2.8 pg/mL. Elevated levels are associated with inflammatory conditions and predict lower chances of survival in COVID-19 patients.

    Measured: Baseline and day 11 or discharge, whichever comes first.

Secondary outcomes (2)

  1. Median change from baseline to day 56 in World Health Organization (WHO) Scale Assessment of COVID-19 Symptom Severity

    The WHO Scale secondary outcome measure is the median change from baseline to day 56. This ordinal Scale is from 0 (no clinical/virological evidence of infection) to 8 (death). Scale assessments are made on patients on days 1-14, 21, 28, 42 and 56. Scale assessments of discharged patients are made during a home visit by a study nurse.

    Measured: Baseline and day 56 or death, whichever comes first

  2. Percent of hospital days with ventilator and/or oxygen use, and percent of hospital days with maximum ventilator pressure and maximum oxygen use

    Daily recording of ventilator and oxygen use (on or off), ventilator pressure, and oxygen use (percent and flow rate) in the morning and evening for patients requiring respiratory assistance. These data will be used to calculate the mean percent of total hospital days with ventilator and/or oxygen use, and the mean percent of days of maximum ventilator pressure and maximum oxygen use from day 1 of ventilator and/or oxygen use to subsequent days.

    Measured: Day 1 (baseline) of ventilator and/or oxygen use until ventilator and/or oxygen use is discontinued

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2022
  2. Study start9 Aug 2021
  3. Primary completion28 Feb 2022 (estimated)
  4. Study completion30 Mar 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Open label study will include 2 cohorts, non-ICU hospitalized and ICU hospitalized patients
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05212532
Sponsor's protocol ID
CL-EOM613-001
Status last verified
Jan 2022
First submitted
25 Aug 2021
Last updated
28 Jan 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Advanced Viral Research Corp. (ADVR). ADVR reports AVR118 inhibits inflammatory arthritis in animal model and in rheumatoid arthritis patients in human clinical trial. ADVR press release, PR Newswire, December 3, 2003.

  • Chasen M, Bhargava R, Hirschman SZ, Taraporewala I. Phase II study of OHR/AVR118 in anorexia- cachexia. Abstract of poster presentation at the 7th Cachexia conference, Kobe/Osaka, Japan, December 9-11, 2013. J Cachexia Sarcopenia Muscle 2013;4(4):335-6.

  • Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J Am Med Dir Assoc. 2011 Jan;12(1):62-7. doi: 10.1016/j.jamda.2010.02.012. Epub 2010 May 15.

    PubMed 21194662

  • COVID-19 Treatment Guidelines, Interleukin-6 Inhibitors. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/. Updated April 21, 2021. Accessed August 24, 2021.

  • Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013 Oct;52(10):855-68. doi: 10.1007/s40262-013-0079-0.

    PubMed 23719681

  • D'Olimpio JT, Chasen MR, Sharma R, Diego M, Gullo V, MacDonald N. Phase II study of AVR118 in the management of cancer-related anorexia/cachexia. Doi: 10.1200/jco.2009.27.15_suppl.e20631 (abstract presentation). Journal of Clinical Oncology 2009; 27, No. 15_suppl., e20631-e20631.

  • D'Olimpio JT, Hirschman SZ, Shtemer Z, Didiego M. Anti-cachectic effects of a novel peptide nucleic acid: Preliminary results of a phase I/II clinical trial. Doi: 10.1200/jco.2004.22.90140.8087 (abstract presentation). Journal of Clinical Oncology. July 15, 2004; 22, no. 14_suppl 8087-8087.

  • Friedland B. In vitro antiviral activity of a peptide-nucleic acid solution against the human immunodeficiency virus and influenza A virus. J R Soc Health. 1991 Oct;111(5):170-1. doi: 10.1177/146642409111100505.

    PubMed 1724467

  • Hirschman SZ, Chen CW. Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus. J Investig Med. 1996 Aug;44(6):347-51.

    PubMed 8795297

  • Hirschman SZ. Activation of human monocytes/macrophages by OHR/AVR118 promotes both pro-and anti-inflammatory phenotypes. Available: https://www.scirp.org/journal/PaperInformation.aspx?paperID=42617. Accessed August 24, 2021. Adv Bioscience Biotechnology. 2014, 5:161-168.

  • Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020 Oct 1;40:37. doi: 10.1186/s41232-020-00146-3. eCollection 2020.

    PubMed 33014208

  • Lazzarino DA, Diego M, Musi E, Hirschman SZ, Alexander RJ. CXCR4 and CCR5 expression by H9 T-cells is downregulated by a peptide-nucleic acid immunomodulator. Immunol Lett. 2000 Nov 1;74(3):189-95. doi: 10.1016/s0165-2478(00)00258-3.

    PubMed 11064099

  • Lazzarino DA, de Diego M, Hirschman SZ, Zhang KY, Shaikh S, Musi E, Liaw L, Alexander RJ. IL-8 and MCP-1 secretion is enhanced by the peptide-nucleic acid immunomodulator, Product R, in U937 cells and primary human monocytes. Cytokine. 2001 May 21;14(4):234-9. doi: 10.1006/cyto.2001.0867.

    PubMed 11448124

  • Levett PN, Hirschman SZ, Roach TC, Broome H, Alexander RJ, Fraser HS. Randomized, placebo-controlled trial of product R, a peptide-nucleic acid immunomodulator, in the treatment of adults infected with HIV. HIV Clin Trials. 2002 Jul-Aug;3(4):272-8. doi: 10.1310/N34A-653T-ABF5-8Q1R.

    PubMed 12187500

  • Scherger S, Henao-Martinez A, Franco-Paredes C, Shapiro L. Rethinking interleukin-6 blockade for treatment of COVID-19. Med Hypotheses. 2020 Nov;144:110053. doi: 10.1016/j.mehy.2020.110053. Epub 2020 Jun 27.

    PubMed 32758889

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing EOM613 in people with COVID-19 Pneumonia and COVID-19 Respiratory Infection, run by EOM Pharmaceuticals at 4 sites in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Melina Szkelnik-Sidi, BS (+ 55 11 98258-6261, melina.sidi@azidusbrasil.com.br), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline to day 11 in mean blood urea nitrogen (BUN) level. (time frame: Baseline and day 11 or discharge, whichever comes first.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05212532, which also lists 16 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jan 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in